A detailed history of Federated Hermes, Inc. transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 11,688 shares of LYEL stock, worth $17,648. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,688
Previous 10,702 9.21%
Holding current value
$17,648
Previous $23,000 30.43%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$1.3 - $3.01 $1,281 - $2,967
986 Added 9.21%
11,688 $16,000
Q1 2024

May 14, 2024

SELL
$1.71 - $3.07 $7,888 - $14,161
-4,613 Reduced 30.12%
10,702 $23,000
Q4 2023

Jan 31, 2024

BUY
$1.39 - $2.35 $3,354 - $5,670
2,413 Added 18.7%
15,315 $29,000
Q3 2023

Nov 13, 2023

SELL
$1.45 - $3.35 $1,364 - $3,152
-941 Reduced 6.8%
12,902 $18,000
Q2 2023

Aug 14, 2023

BUY
$1.89 - $3.86 $26,163 - $53,433
13,843 New
13,843 $44,000
Q4 2022

Feb 13, 2023

SELL
$2.78 - $8.09 $2 - $8
-1 Reduced -0.0%
513,200 $1.78 Million
Q3 2022

Nov 14, 2022

BUY
$5.54 - $8.27 $5 - $8
1 Added 0.0%
513,201 $3.76 Million
Q1 2022

May 13, 2022

BUY
$5.05 - $7.7 $1.55 Million - $2.37 Million
307,700 Added 149.73%
513,200 $2.59 Million
Q4 2021

Feb 14, 2022

SELL
$7.13 - $15.19 $2.24 Million - $4.76 Million
-313,500 Reduced 60.4%
205,500 $1.59 Million
Q3 2021

Nov 15, 2021

SELL
$11.0 - $17.95 $761,585 - $1.24 Million
-69,235 Reduced 11.77%
519,000 $7.68 Million
Q2 2021

Aug 16, 2021

BUY
$15.99 - $16.89 $9.41 Million - $9.94 Million
588,235 New
588,235 $9.55 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $374M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.